combination) subcutaneously at an interval of 2 weeks after the first dose, 1 week and 2 weeks.
Packaging Lumisep®hypodermic injection 210mg syringe: 1 syringe
Approval acquisition date July 4, 2016
Drug price listing date August 31, 2016
Note 1 Psoriasis vulgaris
Psoriasis is a type of chronic skin disorder in which clear erythema with invasion/ thickening appears in the whole body and silvery white scales are observed. Approximately 90% of psoriasis is said to be plaque psoriasis.
2 Arthroscopic psoriasis
In addition to skin symptoms it calls for a disease type accompanied by the symptoms of arthritis. It is not necessarily correlated with the degree of skin rash, it may accompany strong joint swelling and pain. Although it shows symptoms similar to rheumatoid arthritis, rheumatoid reactions are not generally recognized in blood tests.
Note 3 Pustular psoriasis
With psoriasis, it is accompanied by fever and fatigue and calls for a disease type in which many pustules appear with redness on the skin of the whole body. It is severe in psoriasis and is life-threatening systemic inflammatory disease sometimes and it is designated as intractable disease in the country.
Note 4 Psoriatic erythroderma
It means that the rash of psoriasis spreads, spreads throughout the body and becomes red. Often accompanied by fever and malaise.
Note 5 IL-17 receptor A
It forms receptors for the inflammatory cytokines IL-17A, IL-17A/F, IL-17F and IL-17C.
Note 6 IL-17A, IL-17F, etc.
It is an inflammatory cytokine that induces inflammation and immune reactions and is known to be involved in the pathogenesis of autoimmune diseases including psoriasis.
|
